TrialSignal
Clinical trial intelligence report
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 16, 2026
NCT ID
NCT05868382
Status
COMPLETED
Phase
Phase 2
Sponsor
ModernaTX, Inc.
Executive brief
Investment-Ready Snapshot
ModernaTX, Inc. is advancing its mRNA-1010 vaccine candidate through a Phase 2 clinical trial aimed at evaluating safety, reactogenicity, and immunogenicity in healthy adults aged 18 to 49. The influenza vaccine market is highly competitive, with established players like Sanofi and GlaxoSmithKline. The successful development of mRNA-1010 could position Moderna favorably in the seasonal influenza vaccine market, especially given the growing acceptance of mRNA technology post-COVID-19. Diligence should focus on the trial's safety profile and immunogenicity data, which will be critical for regulatory approval and market entry.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05868382
Indication
Influenza
Modality
RNA therapy
Target
mRNA-1010 vaccine candidate variations targeting influenza A and B strains.
Intervention
mRNA-1010, mRNA-1010.4, mRNA-1010.6
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.